You are currently viewing a new version of our website. To view the old version click .
MDPIMDPI
Search all articles
Current Oncology
Submit to Current Oncology

Current Oncology, Volume 28, Issue 5

October 2021 - 80 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
  • You may sign up for email alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Cover Story: Prostate cancer is one of the most commonly diagnosed cancers and the second greatest cause of tumor-related death in men. Prostate-specific membrane antigen is overexpressed on the surface of prostate tumors and metastases, making it an ideal target for prostate cancer diagnosis and therapy. Radionuclide therapies targeting this antigen are currently an option for patients with metastatic castration-resistant prostate cancer. However, the membrane antigen is not prostate-specific and is also expressed by other organs, such as the kidneys and salivary glands. Therefore, these radionuclide therapies directed against these antigens could also affect the functions of such organs.View this paper

Articles (80)

  • Article
  • Open Access
11 Citations
3,599 Views
13 Pages
Download PDF

Omental Macrophagic “Crown-like Structures” Are Associated with Poor Prognosis in Advanced-Stage Serous Ovarian Cancer

  • Yu-Ling Liang,
  • Chang-Ni Lin,
  • Hsing-Fen Tsai,
  • Pei-Ying Wu,
  • Sheng-Hsiang Lin,
  • Tse-Ming Hong and
  • Keng-Fu Hsu
Curr. Oncol.2021, 28(5), 4234-4246;https://doi.org/10.3390/curroncol28050359

19 October 2021

The tumor microenvironment is a well-recognized framework in which immune cells present in the tumor microenvironment promote or inhibit cancer formation and development. A crown-like structure (CLS) has been reported as a dying or dead adipocyte sur...

Full Article
  • Article
  • Open Access
30 Citations
5,158 Views
10 Pages
Download PDF

Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy Database

  • Heidi A. I. Grosjean,
  • Samantha Dolter,
  • Daniel E. Meyers,
  • Philip Q. Ding,
  • Igor Stukalin,
  • Siddhartha Goutam,
  • Shiying Kong,
  • Quincy Chu,
  • Daniel Y. C. Heng and
  • D. Gwyn Bebb
  • + 3 authors
Curr. Oncol.2021, 28(5), 4213-4222;https://doi.org/10.3390/curroncol28050357

18 October 2021

The emergence of immunotherapy revolutionized the treatment of non-small-cell-lung cancer (NSCLC), with multiple landmark clinical trials establishing the efficacy of these agents. However, many patients who receive immunotherapy in clinical practice...

Full Article
  • Article
  • Open Access
2 Citations
2,843 Views
11 Pages
Download PDF

Total Colectomy as a Part of Ultra-Radical Surgery for Ovarian Cancer—Short- and Long-Term Outcomes

  • Sebastian Szubert,
  • Artur Skowyra,
  • Andrzej Wójtowicz,
  • Pawel Pawlowicz,
  • Marek Szczepkowski,
  • Blazej Nowakowski and
  • Lukasz Wicherek
Curr. Oncol.2021, 28(5), 4223-4233;https://doi.org/10.3390/curroncol28050358

18 October 2021

(1) Background: The aim of this study was to assess the outcomes for patients who underwent total colectomy (TC) as a part of surgery for ovarian cancer (OC). (2) Methods: We performed a retrospective analysis of 1636 OC patients. Residual disease (R...

Full Article
  • Article
  • Open Access
2,619 Views
10 Pages
Download PDF

Changes in Health State Utility Values in Japanese Patients with End-Stage Breast Cancer

  • Tsuguo Iwatani,
  • Shinichi Noto and
  • Koichiro Tsugawa
Curr. Oncol.2021, 28(5), 4203-4212;https://doi.org/10.3390/curroncol28050356

18 October 2021

We aimed to determine the dynamic trends in health state utility values (HSUVs) in patients with end-stage breast cancer. We selected 181 patients comprising 137 with primary breast cancer (PBC) and 44 with metastatic breast cancer (MBC) (28 survivor...

Full Article
  • Communication
  • Open Access
12 Citations
3,965 Views
10 Pages
Download PDF

Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group

  • Wei Fang Dai,
  • Vanessa Arciero,
  • Erica Craig,
  • Brent Fraser,
  • Jessica Arias,
  • Darryl Boehm,
  • Nevzeta Bosnic,
  • Patricia Caetano,
  • Carole Chambers and
  • Barry Jones
  • + 13 authors
Curr. Oncol.2021, 28(5), 4174-4183;https://doi.org/10.3390/curroncol28050354

16 October 2021

The Canadian Real-world Evidence for Value in Cancer Drugs (CanREValue) Collaboration was established to develop a framework for generating and using real-world evidence (RWE) to inform the reassessment of cancer drugs following initial health techno...

Full Article
  • Article
  • Open Access
13 Citations
3,738 Views
19 Pages
Download PDF

At the Heart of It All: Emotions of Consequence for the Conceptualization of Caregiver-Reported Outcomes in the Context of Colorectal Cancer

  • A. Fuchsia Howard,
  • Kelsey Lynch,
  • Scott Beck,
  • Maria-José Torrejón,
  • Jonathan Avery,
  • Sally Thorne,
  • Antony Porcino,
  • Mary De Vera,
  • Leah Lambert and
  • Angela Wolff
  • + 4 authors
Curr. Oncol.2021, 28(5), 4184-4202;https://doi.org/10.3390/curroncol28050355

16 October 2021

Colorectal cancer (CRC) can be demanding for primary caregivers; yet, there is insufficient evidence describing the caregiver-reported outcomes (CROs) that matter most to caregivers. CROs refer to caregivers’ assessments of their own health status as...

Full Article
  • Brief Report
  • Open Access
3 Citations
3,397 Views
7 Pages
Download PDF

Single-Center Comparison of [64Cu]-DOTAGA-PSMA and [18F]-PSMA PET–CT for Imaging Prostate Cancer

  • Siroos Mirzaei,
  • Rainer Lipp,
  • Shahin Zandieh and
  • Asha Leisser
Curr. Oncol.2021, 28(5), 4167-4173;https://doi.org/10.3390/curroncol28050353

15 October 2021

Introduction: the diagnostic performance of [64Cu]-DOTAGA-PSMA PET–CT imaging was compared retrospectively to [18F]-PSMA PET–CT in prostate cancer patients with recurrent disease and in the primary staging of selected patients with advanced local and...

Full Article
  • Article
  • Open Access
49 Citations
4,278 Views
10 Pages
Download PDF

Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma

  • Yuji Eso,
  • Haruhiko Takeda,
  • Kojiro Taura,
  • Atsushi Takai,
  • Ken Takahashi and
  • Hiroshi Seno
Curr. Oncol.2021, 28(5), 4157-4166;https://doi.org/10.3390/curroncol28050352

14 October 2021

Background: Combination therapy with anti-programmed death-ligand 1 monoclonal antibody atezolizumab plus anti-vascular endothelial growth factor agent bevacizumab (Atezo/Bev) was approved in 2020 as a first-line treatment for unresectable hepatocell...

Full Article
  • Review
  • Open Access
16 Citations
3,704 Views
9 Pages
Download PDF

Incidence, Etiology, Prevention and Management of Ureteroenteric Strictures after Robot-Assisted Radical Cystectomy: A Review of Published Evidence and Personal Experience

  • Shintaro Narita,
  • Mitsuru Saito,
  • Kazuyuki Numakura and
  • Tomonori Habuchi
Curr. Oncol.2021, 28(5), 4109-4117;https://doi.org/10.3390/curroncol28050348

13 October 2021

Benign ureteroenteric anastomosis strictures (UESs) are one of many critical complications that may cause irreversible disability following robot-assisted radical cystectomy (RARC). Previous studies have shown that the incidence rates of UES after RA...

Full Article
  • Article
  • Open Access
3 Citations
4,390 Views
11 Pages
Download PDF

Impact of Split Dosing the First Rituximab Infusion in Patients with High Lymphocyte Count

  • Maude Plante,
  • Laurence Garneau,
  • Magali Laprise-Lachance,
  • Pierre Lemieux and
  • Michel Dorval
Curr. Oncol.2021, 28(5), 4118-4128;https://doi.org/10.3390/curroncol28050349

13 October 2021

The most common adverse reactions to rituximab are infusion-related reactions (IRR). We evaluated the efficacy of split dosing the first rituximab infusion over two days to reduce IRR incidence in patients with hematological cancer and a high lymphoc...

Full Article

of 8

Go to next page